MRNA - Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility | Benzinga
The U.S. Food and Drug Administration (FDA) identified several quality control issues at the primary manufacturing facility of Moderna Inc. (NASDAQ: MRNA) during a September inspection.
This revelation comes from a report obtained through a Freedom of Information Act request, highlighting concerns at the Norwood, Mass., plant, according to a news report by Reuters.
The report said that the facility is crucial in the production of Moderna's COVID-19 vaccine, Spikevax, and an experimental mRNA cancer vaccine in collaboration with Merck & Co (NYSE: MRK).
Inspection Findings
The FDA's findings revealed lapses in equipment cleaning verification and the use of expired materials, raising concerns ...